PTC Therapeutics Announces Initiation of a Registration-Directed Clinical Trial to Evaluate Vatiquinone in Mitochondrial Epilepsy October 27, 2020
U.S. FDA Grants Fast Track Designation for ASP0367/MA-0211, a Selective PPARD Modulator being Developed for the Treatment of Primary Mitochondrial Myopathies October 26, 2020